Radiopharm Theranostics Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of September 2026 for Radiopharm Theranostics Limited, a foreign private issuer headquartered in Carlton South, Victoria, Australia. The report serves to disseminate a public announcement made to the Australian Securities Exchange on September 14, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a corporate event rather than a financial statement.
Material Changes and Corporate Events
The primary material event reported is the Company's oral presentation at the SNO26 conference regarding Phase IIb clinical data for its candidate drug, RAD101. A copy of this presentation is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide specific financial guidance, management commentary on future performance, or a detailed discussion of risks and contingencies beyond the standard legal disclaimer that the report is not deemed "filed" for purposes of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review the attached Exhibit 99.1 for the specific clinical data results of the RAD101 Phase IIb trial presented at SNO26.
- Verify the Company's current cash runway and funding status in subsequent filings, as this 6-K contains no financial data.
- Monitor upcoming regulatory filings for any updates on the RAD101 development timeline following the SNO26 presentation.